Canopy Therapeutics: 'Bispecific antibody ADC shows excellent anti-tumor efficacy and tolerability'
Predicted impact: Low· Actual: −3.3% vs sector, volume 4.3× normal (5 trading days)
Same ADC anti-tumor efficacy data already reported in the last 14 days; no new size.